| Mon 16 Nov 2026 |
| Quarterly Report — 2026.09 | 10-Q | DART |
| Fri 13 Nov 2026 |
| Insider Ownership Report | 4 | EN form |
| Share Buyback Results | 8-K | EN form |
| Mon 02 Nov 2026 |
| Material Information for Investment Decisions — CTP13SC — Part1&2 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 승인(Part1&2) (류마티스 관절염 환자)) | 8-K | EN |
| Fri 30 Oct 2026 |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Tue 27 Oct 2026 |
| [Amendment] Preliminary Consolidated Operating Results (Fair Disclosure) | 8-K/A | DART |
| Beneficial Ownership Report (5%) — Standard Form | SC 13D/G | DART |
| Mon 26 Oct 2026 |
| Material Event Report — Share Buyback Decision | 8-K | EN |
| Thu 22 Oct 2026 |
| Material Information for Investment Decisions 투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결) | 8-K | DART |
| Tue 20 Oct 2026 |
| Share Buyback Results | 8-K | DART |
| Wed 14 Oct 2026 |
| Material Information for Investment Decisions — CTP13SC 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인) | 8-K | DART |
| Mon 12 Oct 2026 |
| Preliminary Consolidated Operating Results (Fair Disclosure) | 8-K | DART |
| Tue 29 Sep 2026 |
| Material Event Report — Share Buyback Decision | 8-K | DART |
| Wed 23 Sep 2026 |
| Material Information for Investment Decisions — CTP13SC 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인) | 8-K | DART |
| Beneficial Ownership Report (5%) — Standard Form | SC 13D/G | DART |
| Mon 21 Sep 2026 |
| Material Information for Investment Decisions — CTP44 — Part1&2 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2)) | 8-K | DART |
| Wed 16 Sep 2026 |
| Share Cancellation Decision | 8-K | DART |
| Share Buyback Results | 8-K | DART |
| Mon 07 Sep 2026 |
| Material Information for Investment Decisions — CTP51 투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인) | 8-K | DART |
| Material Information for Investment Decisions — CTP44 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인) | 8-K | DART |
| Mon 31 Aug 2026 |
| Ad-hoc Disclosure Matters — Fair Disclosure | 8-K | DART |
| Material Event Report — Share Buyback Decision | 8-K | DART |
| Fri 28 Aug 2026 |
| Beneficial Ownership Report (5%) — Standard Form | SC 13D/G | DART |
| Other Disclosure 대규모기업집단현황공시[분기별공시(개별회사용)] | Other | DART |
| Tue 25 Aug 2026 |
| Clarification of Rumor or Report — Pending | 8-K | DART |
| Mon 24 Aug 2026 |
| Material Information for Investment Decisions — CTP51 투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품목허가 신청) | 8-K | DART |
| Fri 21 Aug 2026 |
| Insider Ownership Report | 4 | DART |
| Fri 14 Aug 2026 |
| Semi-annual Report — 2026.06 | 10-Q | DART |
| Other Disclosure 지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항 | Other | DART |
| Mon 03 Aug 2026 |
| Material Information for Investment Decisions — CTP44 투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청) | 8-K | DART |
| Beneficial Ownership Report (5%) — Short Form | SC 13D/G | DART |
| Fri 31 Jul 2026 |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Insider Ownership Report | 4 | DART |
| Thu 30 Jul 2026 |
| Material Information for Investment Decisions — CTP55 투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 미국 품목허가 신청) | 8-K | DART |
| Mon 27 Jul 2026 |
| [Amendment] Preliminary Consolidated Operating Results (Fair Disclosure) | 8-K/A | DART |